Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960568 · ClinicalTrials.gov registry record · Phase 1
Genetic Variability in CYP2D6 in U.S Active Duty Population
A Phase 1 study, sponsored by Walter Reed Army Institute of Research (WRAIR).
- Completed
- Registry status
- Phase 1
- Development phase
- 550
- Enrollment target
NCT02960568 is a Phase 1 study that has completed, run by Walter Reed Army Institute of Research (WRAIR). The registered enrollment target is 550 participants.
The verdict
NCT02960568, a Phase 1 study, has completed, sponsored by Walter Reed Army Institute of Research (WRAIR).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 550 participants
- Enrollment target
Study Summary
The investigator proposes to 2D6 (Cytochrome P-450 Isoenzyme 2D6) genotype and phenotype a group of active duty service members and assess the effects on primaquine metabolism.
Interventions
- DRUG Primaquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2016-01-08 |
| Est. Completion | 2017-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02960568
The ClinicalTrials.gov registry entry for NCT02960568 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Walter Reed Army Institute of Research (WRAIR), which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Primaquine is the first listed.
NCT02960568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02960568 about?
NCT02960568 is a clinical study titled "Genetic Variability in CYP2D6 in U.S Active Duty Population". The investigator proposes to 2D6 (Cytochrome P-450 Isoenzyme 2D6) genotype and phenotype a group of active duty service members and assess the effects on primaquine metabolism.
What is the current status of trial NCT02960568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 550 participants. The study started on 2016-01-08. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02960568?
The interventions under investigation include: Primaquine (DRUG).
Who is sponsoring clinical trial NCT02960568?
This trial is sponsored by Walter Reed Army Institute of Research (WRAIR), which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.